Despite guidelines that recommend genetic testing for patients at increased risk of carrying a pathogenic variant in a breast cancer gene (e.g. BRCA1, BRCA2, CHEK2, PALB2, ATM) [[1], [2], [3]] not all eligible patients are referred for genetic testing. This evidence concerns the gene BRCA1 and breast carcinoma.